Health & Fitness
Tue, October 23, 2012Mon, October 22, 2012Sun, October 21, 2012Sat, October 20, 2012Fri, October 19, 2012Thu, October 18, 2012Wed, October 17, 2012Tue, October 16, 2012Mon, October 15, 2012Sun, October 14, 2012Fri, October 12, 2012Thu, October 11, 2012Wed, October 10, 2012Tue, October 9, 2012Mon, October 8, 2012Sun, October 7, 2012Sat, October 6, 2012Fri, October 5, 2012Thu, October 4, 2012Wed, October 3, 2012Tue, October 2, 2012Regeneron to Report Third Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on October 24, 2012
Published in Health and Fitness on Wednesday, October 10th 2012 at 7:00 GMT by Market Wire
Regeneron to Report Third Quarter 2012 Financial and Operating Results and Host... -- TARRYTOWN, N.Y., Oct. 10, 2012 /PRNewswire/ --
Regeneron to Report Third Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on October 24, 2012
TARRYTOWN, N.Y., Oct. 10, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)today announced that it will report its third quarter 2012 financial and operating results on Wednesday, October 24, 2012, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM EST that day.
Conference Call Information
To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International). A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at [ www.regeneron.com ]. A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].
Contact Information: | |
Manisha Narasimhan, Ph.D. | Peter Dworkin |
Investor Relations | Corporate Communications |
914-847-5126 | 914.847.7640 |
SOURCE Regeneron Pharmaceuticals, Inc.
[ Back to top ]
RELATED LINKS
[ http://www.regeneron.com ]
